Lisa Bhatt

Lisa Bhatt investigates immunotherapy for ovarian cancer, focusing on identifying patient populations most likely to benefit from checkpoint inhibitors. Her research characterized the tumor immune microenvironment of high-grade serous ovarian cancer and identified TIL infiltration patterns that predict clinical outcomes. She has studied pembrolizumab and atezolizumab in combination with PARP inhibitors and anti-angiogenic agents for recurrent ovarian cancer. Her work aims to overcome the traditionally immunosuppressive tumor microenvironment of ovarian cancer.